Peptide Initiative

Peptides · Peptide comparison

Acetyl Hexapeptide-3 (Argireline) vs Myristoyl Pentapeptide-17

SNARE complex inhibitor that reduces expression wrinkles through topical neuromuscular modulation — the 'Botox in a bottle' peptide.

Keratin-stimulating lipopeptide specifically designed to enhance eyelash and eyebrow growth through hair follicle activation.

  • Cosmetic
  • Cosmetic

At a glance

Quick comparison

Dose rangeAcetyl Hexapeptide-3 (Argireline)5–10 %Myristoyl Pentapeptide-170.001–0.1 %
FrequencyAcetyl Hexapeptide-3 (Argireline)Once dailyMyristoyl Pentapeptide-17Once daily
AdministrationAcetyl Hexapeptide-3 (Argireline)TopicalMyristoyl Pentapeptide-17Topical
Cycle lengthAcetyl Hexapeptide-3 (Argireline)Ongoing/indefiniteMyristoyl Pentapeptide-17Ongoing/indefinite
Onset speedAcetyl Hexapeptide-3 (Argireline)Moderate (1-2 weeks)Myristoyl Pentapeptide-17Moderate (1-2 weeks)
Evidence levelAcetyl Hexapeptide-3 (Argireline)Limited human trialsMyristoyl Pentapeptide-17Limited human trials

Efficacy

Benefit ratings

Expression Wrinkle Reduction

Acetyl Hexapeptide-3 (Argireline)85%
Myristoyl Pentapeptide-17No recorded rating

Non-Invasive Treatment

Acetyl Hexapeptide-3 (Argireline)92%
Myristoyl Pentapeptide-17No recorded rating

Safety Profile

Acetyl Hexapeptide-3 (Argireline)95%
Myristoyl Pentapeptide-1795%

Eyelash Growth

Acetyl Hexapeptide-3 (Argireline)No recorded rating
Myristoyl Pentapeptide-1785%

Hair Strengthening

Acetyl Hexapeptide-3 (Argireline)No recorded rating
Myristoyl Pentapeptide-1780%

Technical data

Compound specifications

Acetyl Hexapeptide-3 (Argireline)

Molecular formula
C35H62N14O11S
Molecular weight
887.0 Da
Half-life
Topical stability dependent on formulation; methionine residue susceptible to oxidation; stable at pH 5.5-7.7
Bioavailability
Limited skin penetration (0.22-0.54%); primarily acts at stratum corneum and superficial epidermis; O/W emulsions enhance delivery
CAS number
616204-22-9

Myristoyl Pentapeptide-17

Molecular formula
C41H81N9O6
Molecular weight
796.2 Da
Half-life
Topical application; sustained follicular activity with daily reapplication
Bioavailability
Enhanced follicular penetration via myristic acid (C14) lipid conjugation
CAS number
959610-30-1

Protocols

Dosing compared

Acetyl Hexapeptide-3 (Argireline)

Topical

  • 5-10% concentration (cream or serum)Twice daily (morning and evening) · Minimum 28-30 days; ongoing use to maintain effectUsed as a leave-on skin cream or serum. In studies, a 10% formula applied twice a day around the eyes reduced wrinkle depth by about 17% after 15 days and up to 27-30% after 30 days. It works on the skin surface only and is not injected. [1][2]

Myristoyl Pentapeptide-17

Topical

  • 0.001-0.1% in finished serum (supplied as a 0.1% / 1000 ppm active solution)Once or twice daily to lash line / brows · 8-16 weeks for visible lash effectCosmetic lash/brow active applied to the lash line; typical eye-area use concentrations and the 1000 ppm supplier solution define the formulation dose [6]. Topical only; not dosed systemically.

Applications

Best suited for

Acetyl Hexapeptide-3 (Argireline)

Individuals seeking non-invasive reduction of expression lines and dynamic wrinkles
Acetyl Hexapeptide-3 (Argireline) is particularly well-suited for individuals focused on individuals seeking non-invasive reduction of expression lines and dynamic wrinkles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][4].
Those with needle phobia who want botulinum toxin-like effects without injections
Acetyl Hexapeptide-3 (Argireline) is particularly well-suited for individuals focused on those with needle phobia who want botulinum toxin-like effects without injections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [4].
People targeting crow's feet, forehead lines, and glabellar creases
Acetyl Hexapeptide-3 (Argireline) is particularly well-suited for individuals focused on people targeting crow's feet, forehead lines, and glabellar creases. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Individuals looking for preventive anti-wrinkle treatment to slow expression line formation
Acetyl Hexapeptide-3 (Argireline) is particularly well-suited for individuals focused on individuals looking for preventive anti-wrinkle treatment to slow expression line formation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Myristoyl Pentapeptide-17

Individuals seeking longer, fuller eyelashes without prostaglandin-based prescriptions
Myristoyl Pentapeptide-17 is particularly well-suited for individuals focused on individuals seeking longer, fuller eyelashes without prostaglandin-based prescriptions. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those with naturally thin or sparse eyebrows wanting natural enhancement
Myristoyl Pentapeptide-17 is particularly well-suited for individuals focused on those with naturally thin or sparse eyebrows wanting natural enhancement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
People recovering from lash or brow loss due to extensions, aging, or over-plucking
Myristoyl Pentapeptide-17 is particularly well-suited for individuals focused on people recovering from lash or brow loss due to extensions, aging, or over-plucking. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Users wanting a gentle peptide-based alternative to bimatoprost (Latisse)
Myristoyl Pentapeptide-17 is particularly well-suited for individuals focused on users wanting a gentle peptide-based alternative to bimatoprost (latisse). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Acetyl Hexapeptide-3 (Argireline)

Common

  • Mild Skin Irritation
  • Transient Redness
  • Slight Dryness
  • Stinging on Compromised Skin

Uncommon

  • Contact Dermatitis

Serious

  • Allergic Contact Dermatitis

Myristoyl Pentapeptide-17

Common

  • Mild Tingling at Lash Line
  • Temporary Eyelid Dryness
  • Product Residue Buildup
  • Lash Shedding During Initial Phase

Uncommon

  • Periorbital Sensitivity

Serious

  • Allergic Contact Reaction
  • Lipid Peroxidation and Oxidative Stress

Research status

Safety & evidence

Acetyl Hexapeptide-3 (Argireline)

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Acetyl Hexapeptide-3 demonstrates an excellent safety profile for topical cosmetic use with no serious adverse events reported in clinical studies. At the 10% concentrations used in cosmetic formulations, systemic absorption is minimal and no neurotoxicity has been observed despite its mechanism of action on the neuromuscular junction. In cell-culture testing, significant cytotoxicity appeared only at concentrations 18 to 10,000 times higher than the reference drug doxorubicin [5]. Primary concerns are limited to local skin irritation in sensitive individuals, such as mild erythema, transient stinging, or contact dermatitis in those with peptide hypersensitivity.

Contraindications

  • Known hypersensitivity to acetyl hexapeptide-3 or formulation components
  • Active skin infections or open wounds at the application site
  • No known systemic contraindications at cosmetic concentrations
  • Use with caution in individuals with neuromuscular disorders (theoretical concern)

Myristoyl Pentapeptide-17

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Myristoyl pentapeptide-17 demonstrates excellent cosmetic safety with GRAS/safe-for-use status in topical formulations up to 3% concentration. No serious adverse events in 10+ years of cosmetic industry application; mild skin irritation rare (<1%) at recommended concentrations. Dermal penetration limited to epidermis; no systemic absorption in vitro. Well-tolerated in combination with other anti-aging ingredients; photostability adequate for cosmetic formulations.

Contraindications

  • Known hypersensitivity to myristoylated peptides or formulation components
  • Active eye infections, styes, or periorbital dermatitis
  • Post-surgical eye conditions where topical application is contraindicated
  • Concurrent use of prescription eyelash growth products without medical guidance

Decision guide

Which is right for you?

Acetyl Hexapeptide-3 (Argireline)

Choose Acetyl Hexapeptide-3 (Argireline) if…

  • Individuals seeking non-invasive reduction of expression lines and dynamic wrinkles
  • Those with needle phobia who want botulinum toxin-like effects without injections
  • People targeting crow's feet, forehead lines, and glabellar creases
  • Individuals looking for preventive anti-wrinkle treatment to slow expression line formation

Myristoyl Pentapeptide-17

Choose Myristoyl Pentapeptide-17 if…

  • Individuals seeking longer, fuller eyelashes without prostaglandin-based prescriptions
  • Those with naturally thin or sparse eyebrows wanting natural enhancement
  • People recovering from lash or brow loss due to extensions, aging, or over-plucking
  • Users wanting a gentle peptide-based alternative to bimatoprost (Latisse)